Intensity Therapeutics (INTS) Total Liabilities (2022 - 2026)

Intensity Therapeutics (INTS) has 5 years of Total Liabilities data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Total Liabilities fell 15.34% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 15.34% YoY) and the FY2025 annual result came in at $2.2 million, up 19.3% from the prior year.
• Total Liabilities improved to $2.3 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $6.9 million in Q4 2022 to a low of $904857.0 in Q3 2023.
• A 5-year average of $2.9 million and a median of $2.4 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 168.99% in 2024, down 54.88% in 2024.
• Tracing INTS's Total Liabilities over 5 years: stood at $6.9 million in 2022, then tumbled by 39.71% to $4.1 million in 2023, then sank by 54.88% to $1.9 million in 2024, then increased by 19.3% to $2.2 million in 2025, then advanced by 3.91% to $2.3 million in 2026.
• The last three Total Liabilities figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.